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Abstract
Intracellular Ca2+ signaling and Ca2+ homeostasis have long been an important subject 
area of cell biology. Several intracellular Ca2+ binding proteins have been demonstrated 
until now, and among these, annexins are characterized by their ability to interact with 
membrane phospholipids and they form an evolutionary conserved multigene family 
with the members being expressed throughout animal and plant kingdoms. Annexin 
proteins are defined by different structural and biochemical criteria, and this multigene 
family has several biological features. In certain clinical conditions, the alterations on 
the localization or expression levels of annexin proteins are considered as the causes of 
pathological results and/or sequelae of disease. So, annexin proteins are indirectly linked 
to severe human diseases such as cardiovascular disease and cancer. Since annexin pro-
teins are known to play roles in cancer, the researches are focused on defining the clinical 
significance of certain annexin proteins in cancer development and by the way anticancer 
treatments in the last decades. This chapter presents detailed information about annexin 
proteins and the studies on anticancer drug development targeting certain annexins. The 
studies denominate that targeting of certain annexin proteins reduces tumorigenesis 
and therapeutic resistance. So, annexin proteins have growing importance for anticancer 
drug development.
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1. Introduction
Annexins are commonly known to be a large multigene family of Ca2+-dependent phospho-
lipid-binding proteins.They were discovered in the late 1970s and before the name “annexin”, 
they were first introduced in diverse names which in Greek means “hold together” [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
Over a hundred annexin proteins have been discovered in various species. Among these, 12 
proteins are found in humans referred as A1–A13 (leaving A2 unassigned) [2], each having a 
differently positioned calcium/membrane-binding site within the core domain and a different 
N-terminal domain [3].
Annexins have a unique structure that allows them to locate onto membranes reversibly. 
They contain a conserved calcium and membrane-binding unit, which constitutes the core 
domain. It consists of four annexin repeats of about 70–80 amino acids. Its alfa-helical 
shape forms a slightly curved disc. The convex surface of it carries the calcium and mem-
brane-binding sites as well as binding sites for phospholipids, heparin, and F-actin. The 
concave side on the other hand is responsible for other interactions. Ahead of the core 
domain comes the N-terminal region which differs in length and in sequence. It mediates 
regulatory interactions with protein ligands and annexin-membrane association [2]. It has 
been recently demonstrated that a part of N-terminal region integrates into the folded core, 
allowing the N-terminal region to be exposed for additional interactions upon calcium 
binding [4].
2. Functions of annexins
Annexins are responsible for calcium-regulated endocytotic and exocytotic events along with 
stabilizing organelle membranes and the plasma membrane [3]. One of the major roles of 
annexins is acting as scaffold proteins through calcium-regulated binding to phospholip-
ids on the membranes. This allows the cytoplasm and the cytoplasmic side of the cell mem-
brane to interact accordingly [5]. Mobilization of intracellular calcium triggers annexins to be 
recruited by cell membranes. However, some annexins can bind to membranes in the absence 
of calcium as well, such as annexins A9 and A10 [2].
Some annexin members specifically engage with certain sites of actin assembly at cellular 
membranes. For instance, the organization of raft and non-raft microdomains of smooth mus-
cle cell membranes is regulated by annexins A2 and A6 through mediating interactions with 
the cytoskeleton [6].
2.1. Intracellular activities of annexins
Annexins are able to engage with cytoskeleton components reversibly. However, under cer-
tain circumstances, some annexins (A2 and A11) are found to be working together in the 
nucleus in the cell cycle [7]. Especially, annexin A11 plays an essential role in the terminal 
phase of cytokinesis. Without it, cells cannot form a midbody and hence end up in apoptosis 
[8]. Additionally, some annexins can be present on the cell surface. For instance, when cells 
are exposed to glucocorticoids, annexin A1 is found to be translocating from the cytosol to 
the cell surface [9]. It has also been demonstrated that annexin A2 functions as a co-receptor 
for plasminogen in several cell types including tumor cells, macrophages, and endothelial 
cells. There is also evidence that annexin A2 might be taking part in preserving vascular 
patency [10].
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2.2. Extracellular activities of annexins
Annexins are typically known to be cytosolic proteins. However, some annexins can be found 
in extracellular fluids as well. There are binding sites on the outer side of cell membranes 
for these annexins, and they take part in several extracellular functions such as the role of 
annexin A5 as an anticoagulant protein, annexin A2 as an endothelial cell surface receptor for 
plasminogen, and the role of annexin A1 with anti-inflammatory activities on leukocytes [11]. 
As it is mentioned, annexin A2 functions as a receptor for plasminogen through its activities 
in fibrinolytic cascade as a positive modulator [12]. As a result, overexpression of annexin A2 
on the surface of acute promyelocytic leukemia cells could lead to occurrence of bleeding [13].
Annexin A1 is the first member of the annexin family known to be present extracellularly. There 
are several findings about the extracellular activity of annexin A1. It can be found in human 
serum, particularly in inflammatory events such as colitis and myocard infarctus [14]. Even 
though annexins A1 and A4 are both present in ductal prostate epithelium cells, only annexin 
A1 is present extracellularly [15]. Several studies have shown that annexin A1 strongly inhibits 
the transendothelial migration of leukocytes, hence limiting the extent of inflammation [16].
3. Association of annexin proteins with diseases
The absence of annexin proteins can cause several abnormalities in the body. Altered expres-
sion of annexin A1 has led to a change in the inflammatory response of glucocorticoids and 
an increase in leukocyte migration. Additionally, it has been demonstrated that expression of 
other annexin proteins was affected by the loss of annexin A1 as well [17].
Recent studies have revealed that there are single-nucleotide polymorphisms (SNPs) in the 
genome of annexin proteins. According to studies, annexin A2 gene SNP exists in a higher 
level in sickle cell patients compared to control groups and is associated with osteonecrosis 
[18], and annexin A5 gene polymorphism has a role in recurrent pregnancy loss [19].
Annexins also take part in autoimmune diseases such as rheumatoid arthritis and type 1 
diabetes. High levels of annexin V cause annexin V autoantibodies to be produced more than 
necessary, which may play a role in pathogenesis of these diseases [20, 21]. On the other 
hand, annexin A11 gene polymorphism is found to be associated with sarcoidosis, which 
is another autoimmune disease characterized by accumulation of epithelioid granulomas in 
many organs such as kidney and lungs [22].
4. Role of annexins in cancer
Annexin proteins generally exhibit diverse functions in coagulation, inflammation, signal trans-
duction, cell proliferation, apoptosis, tumor development, angiogenesis, invasion/metastasis, and 
drug resistance. Several studies have revealed that annexins might be playing an important role 
in the process of tumor differentiation and tumor development through various mechanisms.
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4.1. Annexin A1 and cancer
Annexin A1 also known as lipocortin is a member of annexin family [23], expressed in many 
cell types such as prostate, brain, epithelial cells, and phagocytes. It participates in various 
intracellular events such as cell growth, migration, cell differentiation, and mediating anti-
inflammatory effects of glucocorticoids [24].
Up-regulation of annexin A1 functions as a tumor progression marker in hepatic, pancre-
atic, breast, and stomach carcinomas [25]. In contrast, it is down-regulated in head and neck 
cancers, prostate cancer, and esophageal cancers [26]. Increased annexin A1 levels have been 
correlated with various multidrug-resistant tumor cells as well. Annexin A1 regulates the 
expression of metastatic matrix metalloproteinase-9 (MMP-9) and its activity and induces the 
activation of NF-kB as well as promoting migration and invasion in MDA-MD-231 cells [27]. 
The studies have reported a significant correlation between annexin A1 levels and pathologi-
cal differentiation of oral squamous cell carcinoma (OSCC) tissues [28]. According to data, the 
presence of annexin A1 also promotes small cell lung cancer (SCLC) cells adherence to brain 
endothelium leading to transendothelial migration [29]. These findings suggest that annexin 
A1 plays an important role in the regulation of tumor cell behavior and can be used as a 
potential target in breast cancer therapy.
4.2. Annexin A2 and cancer
Annexin A2, also known as Calpactin I or Lipocortin II, is a 36 kDa member of annexin family 
expressed by various cell types such as endothelial cells, tumor cells, and macrophages [30]. 
The N-terminal region of annexin A2 contains tissue plasminogen activator (tPA) [31] as well 
as S100A10 protein binding site [32]. On the other hand, the C-terminal region contains hepa-
rin [33], F-actin [3], and plasminogen binding sites [34].
Like the other members of annexin family, intracellular annexin A2 participates in endocy-
totic and exocytotic events. The down-regulation of annexin A2 inhibits cell proliferation 
and cell division [35], and degradation of this protein has been linked with apoptosis pro-
moted by p53-induced pathways [36]. Annexin A2 can also function as an antioxidant. Down-
regulation of annexin A2 leads tumor cells to apoptosis through pro-apoptotic p38MAPK/
JNK/Akt signaling pathways upon hydrogen peroxide exposure [37].
Annexin A2 interacts with tPA which transforms plasminogen into plasmin, hence leading 
to extracellular matrix degradation and cell invasion. However, blocking off the surface of 
annexin A2 can prevent tumor cell growth and metastasis [38]. Overexpression of annexin A2 
is observed in a wide range of cancer cells such as acute lymphoblastic leukemia (ALL), breast 
cancer, colorectal cancer (CRC), lung cancer, and many others.
In acute lymphoblastic leukemia (ALL) cells, annexin A2 has been linked with drug resis-
tance. Experiments revealed that phosphorylated annexin A2 expression (and not annexin 
A2) is higher in prednisolone-resistant cells than in drug-sensitive cell lines, suggesting that 
preventing annexin A2 phosphorylation can bring therapeutic benefit to the treatment of 
drug-resistant ALL cells [39].
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In pancreatic tumors, annexin A2 levels were observed to be 2- to 8-folds higher than in nor-
mal pancreas cells [40]. On the other hand, higher annexin A2 immunoreactivity is observed 
in lung and squamous cell carcinoma compared to control group [41]. The studies also 
suggest that annexin A2-dependent plasmin in human breast cancer cells may participate 
in angiogenesis and metastasis through ubiquitination in breast cancer tissue [42]. Recent 
studies have demonstrated that annexin A2 is a receptor for gastrin and progastric peptides, 
which are associated with growth-stimulatory effects on intestinal epithelial and colon cancer 
cells [43]. Annexin A2 expression is strongly correlated with disease recurrence. Hence, it 
could be regarded as a potential biomarker for CRC patients.
4.3. Annexin A3 and cancer
The absence of annexin A3 is believed to play an important role in drug resistance and tumor 
development. According to available data, there is a correlation between up-regulation of 
annexin A3 and increased drug resistance in ovarian carcinoma. It also increases the metasta-
sis of lung adenocarcinoma and hepatocarcinoma. On the other hand, development of pros-
tatic and renal carcinoma was observed with the down-regulation of annexin A3 [44].
Among digestive tract cancers, colorectal cancer (CRC) is seen very commonly. Since it 
bears no clinical symptoms at early stages, discovering a biomarker that will aid in diag-
nosis has become necessary. Annexin A3 is considered to be a potential biomarker for 
colorectal cancer. The higher level of annexin A3 expression has been determined in blood 
samples of patients with CRC, indicating the importance of annexin A3 as a biomarker in 
CRC [45].
4.4. Annexin A4 and cancer
Annexin A4 is a member of annexin family, also known as lipocortin IV with a size of 35.9 
kDa [46]. It consists of four annexin repeats, and each region includes 5 alfa-helixes with a 
calcium-binding motif [47].
Annexin A4 plays an important role in membrane repair, promoting vesicle aggregation and 
regulation of passive membrane permeability [48]. It also takes part in calcium signaling, anti-
coagulation, and resistance to apoptosis [49]. Accumulated data show that annexin A4 also 
involves in tumor progression, invasion, metastasis, and drug resistance in various cancer 
types [50].
Experiments revealed that there is a positive correlation between annexin A4 and colorectal 
cancer progression [51]. Moreover, annexin A4 was found to be directly binding to HPA (one 
of the markers of CRC metastasis), which indicates that it can be considered an important 
marker for CRC progression [52]. Annexin A4 is also overexpressed in Helicobacter pylori-
infected gastric cancer tissues compared to not infected ones [53]. The suggested mechanism 
is that H. pylori infection promotes gastric cancer progression through increasing annexin A4 
levels in order to induce the expression of IL-8. Hence, annexin A4 can be regarded as a poten-
tial marker in gastric cancer development. The studies also showed the relation of annexin A4 
with malignant mesothelioma [54], breast, laryngeal, and hepatocellular carcinoma [55, 56].
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4.5. Annexin A5 and cancer
Annexin A5, also known as Endonexin II, Lipocortin V, or thromboplastin inhibitor V, plays 
an important role in cell membrane repair during anti-inflammatory, profibrinolytic, and 
anti-thrombotic activities. Intracellular annexin A5 participates in calcium channel activ-
ity on plasma membrane interacting with actin in platelets during the coagulation process 
[57]. On the other hand, extracellular annexin A5 plays an important role in apoptosis and 
phagocytosis [58].
As the most studied member of annexin family, annexin A5 also plays important role in can-
cer development and progression.
Experiments on tumor samples obtained from patients with hepatocellular carcinoma revealed 
that annexin A5 was up-regulated by 134% [59]. Hence, it could be a novel biomarker for 
portal vein tumor thrombus formation. Annexin A5 was also correlated with hepatocar-
cinoma lymphatic metastasis. Half of tumor metastasis occurs through lymphatic system 
leading to poor prognosis. Studies showed that in metastatic hepatocarcinoma, annexin A5 
was increased by 216%, which indicates that annexin A5 levels could be used in diagnosing 
lymphatic metastasis of tumors [60]. Annexin A5 has been found overexpressed in human 
cutaneous SCC cell lines. Experiments showed that annexin A5 is mainly present in growing 
tumor areas [61], suggesting that annexin A5 may involve in cell proliferation and metasta-
sis. On the other hand, knockdown of annexin A5 by siRNA decreased the invasion capabil-
ity of human oral carcinoma cells while up-regulating a metastasis suppressor gene KISS-1 
[62].
Annexin A5 is significantly up-regulated in pancreatic cancer cells under hypoxia condition, 
indicating that it may be a significant reference value in pancreatic ductal adenocarcinoma [63]. 
Results obtained from studies suggest that annexin A5 is involved in breast cancer since up-
regulation of this protein suppressed Raf-1, MEK1/2, and ERK1/2 phosphorylation of breast 
cancer cells [64].
Additionally, the studies revealed that annexin A5 is also involved in cervical, colorectal, 
bladder carcinomas, and inflammation-associated carcinogenesis of fibrosarcoma by different 
mechanisms.
4.6. Annexin A7 and cancer
Annexin A7 (also known as synexin) is a member of annexin family. On human chromosome, 
it is located where several tumor-suppressor genes are present [65]. Although it can be found 
in the nucleus, it is mostly found in membranes [66].
Available data indicate that annexin A7 might function as a tumor-suppressor gene in pros-
tate cancer, melanoma, and glioblastoma; however, it might act as a tumor promoter in gastric 
cancer, liver cancer, colorectal cancer, and breast cancer. Additionally, down-regulation of 
annexin A7 could participate in tumor invasion and metastasis [65].
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5. Annexin-targeted studies
The certain members of annexin family have important functions in the development and 
prognosis of several carcinomas mentioned above. Thus, the studies are focused on targeting 
these proteins to prevent or treat the disease. The recent findings on annexin-targeted treat-
ments are summarized hereafter.
Prostate cancer is the most common malignant cancer diagnosed in men. It accounts for 10% 
of all male cancers and is difficult to detect at early stages. Therefore, it is necessary to discover 
a novel biomarker that will aid in early diagnosis [67]. To investigate the effect of Simvastatin 
and annexin A10 in human PC-3 prostate cancer cells, a nude mouse tumor xenograft model 
was used. Simvastatin was administered with 5 and 50 mg/kg doses. According to results 
obtained, Simvastatin up-regulated the expression of annexin A10 which led to a significant 
decrease in cell proliferation, invasion, and migration as well as a reduction in tumor size. In 
contrast, down-regulation of annexin A10 by siRNA increased the cell proliferation, invasion, 
and migration in PC-3 cells. Taken together, targeting annexin A10 with statins could be used 
in preventing or treating prostate cancer [68].
S100 proteins are known to regulate cell functions through interacting with other proteins, 
particularly with annexins [69]. The interaction between annexin A2 and S100A10 plays an 
important role in tumor metastasis and neo-angiogenesis [70]. Therefore, inhibiting this inter-
action could bring therapeutic benefits in cancer treatment. Several inhibitors have been iden-
tified using biochemical screening and receptor-guided random docking techniques based 
on '1,2,4-triazole' structure. One of these compounds was found to be a potent inhibitor: 
2-[(5-{[(4,6-dimethylpyrimidin-2-yl)sulfanyl]methyl}-4-(furan-2-ylmethyl)-4H-1,2,4-triazol-
3-yl)sulfanyl]-N-[4-(propan-2-yl)phenyl]acetamide [71].
Various chemicals can cause DNA damage and mutagenesis such as As3+ or reactive oxy-
gen species, and mutagenesis has an important role in cancer initiation and progression [72]. 
Annexin A1 is known to participate in signal transduction of growth factors and cell prolif-
eration or differentiation. Nevertheless, in certain types of cancers, the expression of annexin 
A1 can be reduced such as squamous cell carcinoma, whereas it can be increased in other 
cancers such as bladder cancer [73]. Moreover, in some cancer cells, the expression of annexin 
A1 is found higher in nucleus than in cytosol, which indicates that the nuclear presence of 
annexin A1 could correlate with progression of certain cancers [74]. Annexin A1 requires cal-
cium signaling and tyrosine phosphorylation in order to translocate into the nucleus. This 
process is triggered by DNA-damaging agents and oxidative stress [75]. Signals of damage in 
DNA form a mono-ubiquitinated annexin A1, which stimulates translesion DNA synthesis by 
heavy metals [76]. Since annexin A1 is thought to involve in responses of DNA damage and 
mutagenesis, the inhibition of binding activity of annexin A1 by several substances including 
flavonoids has been researched. Results have revealed that Quercetin, Silibinin, and Genistein 
inhibited the binding activity of annexin A1 in a concentration-dependent manner. Moreover, 
they inhibited thymidine kinase gene mutation induced by As3+ in lymphoma cells through 
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suppressing the translesion DNA synthesis which was mediated by mono-ubiquitinated 
annexin A1 in the nucleus [77]. These findings indicate that annexin A1 could be a novel target 
protein in preventing DNA damage induced by gene mutation.
Hepatocarcinoma is one of the most common malignancies with a high mortality rate and 
no effective treatment. A study has shown that in a mouse hepatocarcinoma cell line (Hca-
P), down-regulating the expression of annexin A7 decreases the proliferation and induces 
apoptosis [78]. To investigate the role of it further, an experiment targeting annexin A7 has 
been performed. In order to down-regulate the expression of annexin A7, an RNA interfer-
ence technique (RNAi) was used to demonstrate the changes in cell viability where annexin 
A7 levels are altered after Cisplatin treatment. According to data obtained, following the 
down-regulation of annexin A7, treatment with Cisplatin reduced the proliferation of Hca-P 
cells significantly and induced apoptosis. Additionally, altering the expression of annexin A7 
decreased the expression of Bcl2 and increased the expression of caspase-3 and cytochrome-
C, which indicates that presence of annexin A7 inhibits apoptosis through the mitochondrial 
pathway [79] (see Figure 1).
Annexin A1 is known to participate in the process of inflammation along with a wide range 
of cellular activities [2]. It has been revealed that annexin A1 plays a role in the process of 
apoptosis in inflammatory cells as well [80]. Experiments have shown that elevated annexin 
A1 levels in U937 cells and bronchoalveolar epithelial cells induce apoptosis through cas-
pase-3 activation [81]. Moreover, it has been shown that in thyroid cancer cells, apoptosis 
induced by TRAIL is also mediated through annexin A1 expression [82]. Additionally, in 
Figure 1. Schematic representation of annexin-targeted novel studies (the centered protein figure was prepared by 
Pymol Educational Program using annexin IV protein (PDB ID: 2ZOC) from Protein Data Bank).
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prostate cancer cells, down-regulation of annexin A1 has been suggested to contribute in 
cancer initiation and progression [83]. On the other hand, up-regulation of annexin A1 has 
decreased the cell viability and induced apoptosis through caspase activity [84], which indi-
cates that annexin A1 could be taken as a tumor-suppressor protein in prostate cancer cell 
line (LNCaP).
Experiments have shown that the expression of annexin A1 decreases in prostate cancer cells. 
Therefore, the mechanism of this reduction has been investigated. The fact that annexin A1 
levels only decrease and are not completely eliminated brings the possibility that dysregula-
tion of annexin A1 occurs at the level of gene transcription [85]. It has been proposed that 
deacetylation of histone proteins leads to altered gene expressions [86]. The turnover of his-
tone acetylation is mediated by histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). These enzymes can induce and inhibit transcription [87], and they show dysregu-
lated activities in human cancers leading to neoplastic transformation of tumor cells [88]. 
Hence, the balance of HAT/HDAC has been a target in cancer therapy. Various compounds 
have shown antitumor effects through inhibiting HDACs such as valproic acid and some 
cyclic peptides (FK228) [89].
Recently, a novel compound, FR235222, with inhibitory effect on histone deacetylases has 
been isolated from a fungus [90]. Experiments have revealed that FR235222 induces apoptosis 
and regulates annexin A1 expression in leukemia cell lines. The possible mechanism sug-
gested was that reduced levels of annexin A1 could be mediated by deacetylation of histone 
proteins [85]. To confirm this hypothesis, the effect of FR235222 on apoptosis and annexin A1 
expression has been studied in prostate cancer cell lines (LNCaP). Western blotting results 
have shown that FR235222 induces the expression of annexin A1 in a time-dependent man-
ner with a peak at 48 h. Also, experiments with actinomycin D indicated that the increase of 
annexin A1 was at transcription level. In contrast, when annexin A1 expression was down-
regulated by siRNA transfection protocol, a partial decrease in FR235222-induced apoptosis 
has been observed by 26% and in caspase-3 activity by 22% in LNCaP cells [91]. These find-
ings suggest that transcriptional activation of annexin A1 is induced by FR235222 through 
acetylation of histone proteins and inhibition of HDACs in LNCaP cells, and the increased 
levels of annexin A1 lead to apoptosis through caspase activity.
Lung cancer is one of the most common cancer types with a high rate of mortality [92]. Studies 
have shown that inflammation participates in the development of lung cancer. One of the 
components of inflammatory pathways is the COX-2/PGE
2
 pathway. Increased expression 
of COX-2 is often seen in human non-small cell lung cancer (NSCLC). This leads to over-
expression of PGE
2
 which involves in various cancer-related activities such as resistance to 
apoptosis, angiogenesis, invasion, and metastasis [93]. Annexin A1 acts as a phospholipase 
A2 inhibitor and is associated with several functions such as cell differentiation, cell growth 
arrest, and anti-inflammation [94]. The effect of annexin A1 in human NSCLC cell line (A549) 
has been investigated. Studies have concluded that Dexamethasone increased the expression 
of annexin A1 in A549 cells which inhibited cell growth [95]. In contrast, gene deletion of 
annexin A1 led to an excessive inflammatory stimuli characterized by increased leukocyte 
migration and IL-1B generation [17].
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Green tea (Camellia sinensis leave extract) is known to contain polyphenols which are nat-
ural antioxidants. Accumulated data have shown that green tea exhibits a protective role 
against various cancers including lung cancer [96]. It has been observed that green tea extract 
(GTE) induced annexin A1 in human urothelial cells and in lung cancer (A549) cells in a 
dose-dependent manner [97]. Moreover, GTE-induced annexin A1 also mediated cytoskel-
etal actin remodeling, which led to an increase in cell adhesion and decrease in cell motility. 
Additionally, inhibition of COX-2 and PGE2 was observed in NSCLC cell lines following 
GTE-induced annexin A1 expression. In contrast, silencing annexin A1 expression overturned 
the inhibitory effect of GTE on COX-2. These results suggest that GTE shows its effect through 
inducing annexin A1 expression, therefore targeting annexin A1 could be a promising mecha-
nism in preventing lung cancer [98].
Annexin A2 is present in various cell types including endothelial cells, neuronal cells, and 
cancer cells. It acts as a co-receptor for plasminogen and tissue plasminogen activator (tPA) 
[99]. In acute promyelocytic leukemia (APL) cells, annexin A2 is found to be overexpressed. 
This causes plasmin to be highly produced leading to hyperfibrinolysis and then abnor-
mal bleeding in patients [100]. A study has been performed to investigate the regulation 
of annexin A2 expression in APL cells as well as the effect of arsenic trioxide (As
2
O
3
) and 
all-trans retinoic acid (ATRA). Results have shown that annexin A2 is expressed abnormally 
on the surface of APL cells. Additionally, it has been observed that annexin A2 exhibits a 
unique activity of binding the tPA substrate plasminogen leading to enhanced plasminogen 
activity in APL cells [101]. Following the administration of As
2
O
3
 and ATRA in patients with 
APL, the expression of annexin A2 was significantly down-regulated on the surface of APL 
cells compared to the control group. Bleeding started to disappear a week after the treat-
ment with ATRA and As
2
O
3 
as well as parameters of fibrinolysis [102]. These findings sug-
gest that targeting annexin A2 could help treat the abnormal bleeding in patients with APL.
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